Altimmune, Inc

ALTNASDAQ · Pharmaceutical Preparations

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

194.5M

on 2026-06-30, from 70.9M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

Newest

$400.0M

S-3 of 2025-11-06. 2 prospectus supplements filed under it since. S-3 ↗

$200.0M

Leerink Partners, agreement of 2025-11-06. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

85.75M

Warrants of every class as tagged in the XBRL facts on 2026-06-30, exercise price $2.62. 10-Q ↗

Cash

17.1 quarters

$326.3M on 2026-06-30 ÷ $19.1M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2026-04-24	Public offering incl. 10.75M pre-funded, with warrants at $3.00	75,000,000	$3.00	$225.0M	424B5 ↗
2026-01-27	Registered direct offering incl. 4.65M pre-funded	17,045,454	$4.40	$75.0M	424B5 ↗
2026-01-27	Registered direct offering incl. 4.65M pre-funded	9,295,068	not read	$75.0M	8-K ↗

Also on file: $100.0M term loans, 2025-05-13 8-K ↗ · $100.0M term loans, 2025-11-05 8-K ↗